Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.
After these transactions, Freeman directly holds 60,034 shares of common stock and 701 remaining stock options with a $32.86 exercise price expiring on June 9, 2033. The exercised options come from a June 9, 2023 award that vests over three years.
Guardant Health, Inc. reported a Form 144 notice regarding the sale resulting from an employee stock option exercise on 05/22/2026. The transaction was handled via Charles Schwab & Co., Inc. as a broker payment for cashless exercise of common stock.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported open-market sales of a total of 20,000 shares of common stock on May 20, 2026. The shares were sold in three separate transactions at weighted average prices around $105–$107 per share, each executed across multiple trades within narrow intraday price ranges. These transactions reduce his direct holdings but he continues to own Guardant Health stock after the sales.
Guardant Health, Inc. disclosed that the Talasaz and Eskandari 2017 Family Trust, an entity associated with Co-Chief Executive Officer AmirAli Talasaz, completed a series of open-market sales of the company’s common stock.
The filing shows that the trust sold a total of 210,000 shares of Guardant Health common stock on May 20, 2026, across multiple trades. Reported weighted-average sale prices ranged from about $100.95 to about $112.76 per share, with detailed trade-by-trade pricing available on request from the company or the SEC staff. Following these transactions, the trust held 1,886,504 shares of Guardant Health common stock indirectly attributable to Talasaz.
Guardant Health, Inc. director Ian T. Clark reported an indirect open-market sale of the company’s Common Stock. On May 20, 2026, a family trust associated with him sold 6,876 shares at a weighted average price of $106.9006 per share, in multiple trades between $106.85 and $106.99. Following the transaction, the trust held 2,975 shares of Guardant Health Common Stock indirectly on his behalf, and no derivative securities were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported an option exercise and related stock sales. On May 20, 2026, he exercised stock options to acquire 1,000 shares of common stock at an exercise price of $32.55 per share.
That same day, he completed open-market sales totaling 1,250 shares of common stock, including 250 shares at a weighted-average price of $107.073 per share and 1,000 shares at $107.0956 per share. After these transactions, he directly holds 1,639 shares of Guardant Health common stock and 13,029 stock options with a $32.55 exercise price that expire on July 17, 2034.
Guardant Health submitted a Form 144 notice relating to proposed sales of common stock through a broker. The filing lists broker Charles Schwab & Co., Inc. and shows restricted stock lapses of 1,659 and 5,217 shares on 06/14/2023 and 06/12/2024, respectively.
Guardant Health, Inc. notice of proposed affiliate sales under Form 144. The filing lists scheduled restricted stock lapses of 33 shares on 09/17/2025 and 217 shares on 10/17/2025, and a stock option exercise for 1,000 shares on 05/20/2026 described as a broker payment for a cashless exercise. The filing also reports a sale of 1,300 shares by Manuel Hidalgo Medina on 03/06/2026 for $118,997.